Twice-yearly lenacapavir demonstrates sustained impact on health-related quality of life in people with HIV
— Patient-reported outcomes from the CAPELLA trial align with the demonstrated safety and tolerability profile of lenacapavir
— Analyses show oral bridging maintains virologic suppression when subcutaneous lenacapavir doses are missed
Read the full press release here.
SEE ALSO:
- POZ: Sunlenca pills can bridge gaps when injections are missed
- Contagion Live: Lenacapavir demonstrates safety and efficacy through a year
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.